Immunic’s (IMUX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Immunic (NASDAQ:IMUX) in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has a $17.00 price target on the stock.

Several other brokerages also recently issued reports on IMUX. Leerink Partners reaffirmed an “outperform” rating and issued a $5.00 price target on shares of Immunic in a research report on Monday, September 9th. HC Wainwright started coverage on Immunic in a report on Monday, November 25th. They issued a “buy” rating and a $10.00 target price on the stock. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Leerink Partnrs raised Immunic to a “strong-buy” rating in a research report on Monday, September 9th. Finally, EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a research report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $12.67.

Immunic Price Performance

Shares of NASDAQ:IMUX opened at $1.10 on Tuesday. Immunic has a fifty-two week low of $0.97 and a fifty-two week high of $2.11. The stock has a market capitalization of $99.09 million, a P/E ratio of -0.89 and a beta of 1.88. The business has a 50-day moving average of $1.13 and a two-hundred day moving average of $1.32.

Insider Buying and Selling

In related news, Director Richard Alan Rudick purchased 87,300 shares of the stock in a transaction on Tuesday, November 12th. The shares were purchased at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the transaction, the director now directly owns 87,300 shares of the company’s stock, valued at approximately $100,395. The trade was a ? increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Immunic

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. grew its position in Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares during the last quarter. State Street Corp boosted its stake in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Immunic in the third quarter valued at $50,000. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.